ACT Genomics and mProbe Announces Strategic Integration of Proteomics to Elevate Precision Medicine in Asia

ACT Genomics expands its offerings by exclusively introducing mProbe's OncoOmicsDX, bridging genomics and proteomics for more comprehensive cancer care insights.

TAIPEI, March 6, 2025 /PRNewswire/ -- ACT Genomics Co. Limited, Asia's foremost provider of next-generation sequencing (NGS) precision oncology, is proud to announce a new milestone in its mission to improve cancer patient care: the exclusive integration of OncoOmicsDX, an innovative proteomics clinical service developed by mProbe Inc. in Taiwan, Hong Kong, Macau, Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines.

This collaboration marks a major advancement in integrating genomics and proteomics—also known as proteogenomics—to enhance molecular insights into cancer biology. By combining NGS-based genomic profiling with proteomics-driven biomarker discovery, this approach provides a more comprehensive understanding of tumor biology, uncovering critical mechanisms of disease progression and treatment response.

With these enhanced molecular insights, physicians can make more precise and personalized treatment decisions, optimizing therapy selection based on a patient's unique molecular profile. This proteogenomics approach strengthens the foundation of precision oncology, helping clinicians to identify targeted and effective treatment strategies for cancer patients across the region.

"We are excited to partner with mProbe Inc. to deliver a new dimension in precision oncology," said Dr. Hua Chien Chen, CEO of ACT Genomics. "With OncoOmicsDX, healthcare providers gain a holistic view of cancer biology, allowing them to make data-driven decisions that can significantly improve patient cares."

OncoOmicsDX harnesses advanced mass spectrometry and AI-driven analytics to identify protein biomarkers linked to cancer progression and treatment response. This additional layer of information complements genomic data, creating a more complete patient profile and potentially increasing the effectiveness of personalized treatments. ACT Genomics aims to offer physicians a more holistic picture of their patients' cancer. This integrated approach can better support therapy selection, predict drug resistance, and uncover new therapeutic targets, ensuring that patients receive the most effective, tailored treatment plans.

"This collaboration underscores the critical role proteomics plays in understanding how tumor biology evolves," said Peter Chen, CEO of mProbe Inc. "ACT Genomics' proven track record and extensive network in Asia make them an ideal partner to accelerate the adoption of OncoOmicsDX, ultimately improving patients care across the region."

Through the combined expertise and resources, ACT Genomics and mProbe Inc. are committed to driving the future of precision oncology forward, championing research, clinical innovation, and the integration of multi-omic data for better patient outcome scares. Interested clinicians and researchers can learn more about OncoOmicsDX by contacting ACT Genomics directly.

About ACT Genomics

ACT Genomics is a leading precision medicine company specializing in genomic profiling and advanced molecular diagnostics. Based in Taiwan with operations across Asia, the company provides cutting-edge genomics solutions that empower oncologists to make informed treatment decisions and improve patient care. For more information, please visit https://www.actgenomics.com/.

About mProbe

mProbe Inc. is a global precision diagnostics company specializing in proteomics. Through its advanced mass spectrometry and AI-based platforms, mProbe delivers actionable insights that enhance cancer treatment strategies and improve patient outcomes. For more information, please visit https://www.mprobe.com/.

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

ACT Genomics and mProbe Announces Strategic Integration of Proteomics to Elevate Precision Medicine in Asia

SHANGHAI, May 16, 2026 /PRNewswire/ -- INS LAND, the urban entertainment complex recently ranked No.12 in DJ Mag's 2026 Top 100 Clubs worldwide and No.3 in Asia, announced the opening of three new venues: Soul House, an immersive club; Radi, a fully reimagined and expanded reopening; and Jump, a new high-energy club featuring a spring-loaded dance floor designed to keep guests literally off the ground.

"Soul House, Radi, and Jump are our answer to 2026," said Leo Liu, Cofounder & Head of Brand and Growth at INS LAND. "Each one is a new chapter in INS LAND's vision of bringing the gaming world to life — with a single ticket, guests don't just visit a venue; they enter a world where experiences are reborn every 45 days."

The openings mark a strategic evolution ahead of INS LAND's third anniversary on June 16, 2026, shifting from a "club cluster" identity into a multi-format urban playground. The brand now spans 20 fully owned and operated venues under one ticketed ecosystem.

Soul House is INS LAND's most ambitious immersive concept to date. It features multiple themed rooms, each with its own narrative universe. Guests move through distinct worlds with beverage items, scenography, and storytelling elements, blending immersive theatre and spatial design into a layered experience.

Radi returns after a complete transformation, with an expanded footprint, upgraded sound and lighting systems, and a refreshed design direction positioning it as a signature, design-forward destination within the INS LAND portfolio.

Jump introduces a new experiential format centered on movement. Built around a spring-loaded dance floor, it features high-energy programming across electronic and bounce genres, designed to create a physically kinetic nightlife experience.

About INS LAND

INS LAND is a 20-venue urban entertainment complex in central Shanghai, combining nightlife, immersive experiences, dining, and music under one unified brand. With a single-ticket model granting access across venues, it welcomed over 4 million visitors in 2025 and ranks No.12 globally in DJ Mag's Top 100 Clubs. The platform refreshes its core themes every 45 days and its mobile app supports over 1 million active users across online and offline experiences. INS LAND has collaborated with brands including Mercedes-Benz, Nike, Douyin, Doritos, and Publicis Groupe, and is preparing international expansion with INS LAND Bangkok planned for 2027.

More information: INS LAND Official Site

** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **

Shanghai's INS LAND Unveils Three New Immersive Venues -- Soul House, Radi, and Jump